|Dr. David S. Tierney M.D.||Pres, CEO, CFO & Director||440.27k||N/A||1964|
|Dr. Kin Foong Chan||Exec. VP of Research & Technology||270k||N/A||1974|
|Ms. Joyce Goto||VP, Chief Accounting Officer & Controller||N/A||N/A||1974|
BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trial for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in San Jose, California.
BioPharmX Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.